Prostate cancer patients for Prostate Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
University of Kentucky, Lexington, KY
Prostate Cancer+1 More
ArtemiCoffee - Drug
Eligibility
18+
Male
What conditions do you have?
Select

Study Summary

Until now, clinicians have been challenged to improve the treatment of biochemically recurrent (BCR) prostate cancer in which prostatic specific antigen (PSA) rises without radiological or clinical progression years after localized treatment (radical prostatectomy or radiation therapy) with or without hormonal treatment. Approximately 50-90% of men with high-risk prostate cancer will experience a BCR. Artesunate has demonstrated anti-tumor activity in both in vivo and in vitro cell lines. It is hypothesized that Artemisia annua (Aa) coffee has the potential to decrease rising PSA among patients with biochemical recurrence of prostate cancer.

Eligible Conditions

  • Prostate Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Prostate Cancer

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 24 weeks (Baseline, 3-mos, 6-mos and post-treatment)

24 weeks
Proportion of patients who achieve a 50% decline in PSA levels
Week 24
Change in PSA velocity and slope from pre-treatment to post-treatment
Change in plasma concentration of artemisinin and dihydroartemisinin
Week 24
Percentage change in serial PSA
Percentage change in serial testosterone levels

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Prostate Cancer

Trial Design

1 Treatment Group

Prostate cancer patients
1 of 1
Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Prostate cancer patients · No Placebo Group · Phase 2

Prostate cancer patients
Drug
Experimental Group · 1 Intervention: ArtemiCoffee · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 24 weeks (baseline, 3-mos, 6-mos and post-treatment)
Closest Location: University of Kentucky · Lexington, KY
Photo of Lexington  1Photo of Lexington  2Photo of Lexington  3
1999First Recorded Clinical Trial
4 TrialsResearching Prostate Cancer
360 CompletedClinical Trials

Eligibility Criteria

Age 18+ · Male Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤3.
You are able to understand the nature and risks of the study and you are willing to sign a written informed consent document.
You have completed local therapy for prostate cancer.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.